J Neurosonol Neuroimag Search


J Neurosonol Neuroimag > Volume 13(1); 2021 > Article
Nam, Kwon, Park, and Kwon: High Erythrocyte Sedimentation Rate is Associated with White Matter Hyperintensity in a Healthy Population



High erythrocyte sedimentation rate (ESR) is related to various metabolic, cardiovascular, and cerebrovascular diseases; however, there is a limited study about its association with subclinical cerebral small vessel diseases (cSVDs). In this study, we evaluated the relationship between ESR and cSVDs in a healthy population.


We evaluated healthy check-up volunteers between 2006 and 2013. As subtypes of cSVD, we evaluated white matter hyperintensity (WMH), silent brain infarct (SBI), and cerebral microbleeds (CMBs). The WMH volume was rated quantitatively using a computer-assisted semi-automated technique. SBI and CMBs were evaluated qualitatively for presence.


A total of 2,553 participants were evaluated. In multivariable linear regression analysis, ESR (β=0.027, 95% confidence interval [CI]=0.001 to 0.053, p=0.043) was significantly associated with WMH volumes after adjusting for confounders. Age (β=0.046, 95% CI=0.042 to 0.051, p<0.001), hypertension (β=0.187, 95% CI=0.092 to 0.281, p<0.001), and white blood cell counts (β=0.042, 95% CI=0.018 to 0.067, p=0.001) were also closely related to WMH volumes. ESR did not show any statistical significance with SBI or CMBs. In our data, ESR were closely related to age, sex, diabetes, hyperlipidemia, current smoking, systolic and diastolic blood pressure, and high-sensitivity C-reactive protein.


High ESR was associated with larger WMH volumes in a healthy population. Since this close association was not seen in SBI or CMBs, WMH may be more related to inflammation-related pathologies.


Cerebral small vessel disease (cSVD) is a subclinical pathology, often found in the elderly.1,2 Although cSVDs themselves are asymptomatic, they are clinically important because they increase the risk of ischemic stroke or vascular dementia.3-5 There are subtypes with various pathologies (e.g., white matter hyperintensity [WMH], silent brain infarct [SBI], and cerebral microbleeds [CMBs]) in cSVD. These cSVD subtypes are very different in appearance, but are often found together in brain magnetic resonance imaging (MRI).1,6 In addition, previous autopsy studies have also found a link between them.2,7 Therefore, many studies have been conducted to find the common pathological mechanisms shared between them. Various mechanisms have been proposed as hypotheses, and subclinical inflammation is one of them.7-10
Erythrocyte sedimentation rate (ESR) is an index that reflects the aggregation of red blood cells, and is accelerated by the asymmetry of charged proteins (e.g., fibrinogen, immunoglobulin, lipoprotein) accompanying the occurrence of inflammation.11,12 Since ESR is an inexpensive, validated, and generally available test, it has long been used as a nonspecific inflammatory marker.11-13 In addition, ESR, like other inflammatory markers, has been closely associated with various metabolic diseases, atherosclerosis, cardiovascular diseases, and cerebrovascular diseases.14-18 It is thought that ESR will also have a close relationship with cSVD, which shares similar pathologies with these, but study on this has not been done yet.
In this study, we aimed to evaluate the relationship between ESR and cSVD in a neurologically healthy population. In addition, through comparisons between cSVD subtypes, we would like to examine whether ESR is involved in the common pathological mechanisms of cSVD development or whether it is more closely related to a specific cSVD subtype.


1. Study population

From a consecutive registry at a large medical center in Korea (Seoul National University Hospital Health Promotion Center), we included participants who visited to conduct a voluntary routine health check-up, between January 2006 and December 2013.19 Then, we additionally excluded participants with the following conditions: 1) age under 30 years, 2) history of stroke or severe neurological deficit, 3) hemato-oncologic conditions or use of immunosuppressant, 4) having major surgery or severe trauma, 5) severe hepatic or renal disease, or 6) active infection within prior 2 weeks.19 Finally, a total of 2,553 subjects were included in the final analysis.
This study was approved by the Institutional Review Board (IRB) of the Seoul National University Hospital (IRB No. 1502-026-647). The requirement to obtain informed consent from participants was waived by the IRB due to the retrospective study design using de-identified information. All experiments were performed in accordance with the Declaration of Helsinki and relevant guidelines and regulations.

2. Demographic, clinical, and laboratory assessments

We conducted broad evaluations including age, sex, hypertension (using anti-hypertensive agents, or ≥140 mmHg systolic blood pressure [BP], or ≥90 mmHg diastolic BP), diabetes (using glucose-lowering agents, or ≥6.5% hemoglobin A1c levels), hyperlipidemia (using lipid-lowering agents, or ≥240 mg/dL total cholesterol levels), ischemic heart disease, current smoking, systolic and diastolic BP, and use of anti-platelet agents.19 Blood pressure was checked after 5 minutes rest in sitting position. Laboratory examinations were conducted on the same day after 12 hours of overnight fasting, including glucose profiles, lipid profiles, white blood cell (WBC) counts, high-sensitivity C-reactive protein (hsCRP) and ESR.19

3. Radiological assessments

All participants underwent brain MRI and MRA using 1.5-T MR scanners (Signa, GE Healthcare, Milwaukee, WI, or Magnetom SONATA, Siemens, Munich, Germany). The detailed acquisitions of MRI were as follows: T1-weighted images (repetition time [TR]/echo time [TE]=500/11 ms), T2-weighted images (TR/TE=5,000/127 ms), T2-gradient echo images (TR/TE=57/20 ms), T2 fluid-attenuated inversion recovery images (TR/TE=8,800/127 ms), and three-dimensional time of flight MRA images (TR/TE=24/3.5 ms, slice thickness=1.2 mm). The slice thickness was 5 mm, except for time of flight MRA images.
As subtypes of cSVD lesions, we measured WMH volumes and the presence of SBI and CMBs. WMH volumes were rated quantitatively using Medical Imaging Processing, Analysis, and Visualization (MIPAV, version 7.3.0, National Institutes of Health, Bethesda, MD, USA).19 In this process, we used a computer-assisted semi-automated technique, measuring from converted DICOM files, as in our previous studies.19,20 SBI was defined as an asymptomatic and well-defined lesion larger than 3 mm in size, with signal characteristics same as those of the cerebrospinal fluid on T1- or T2-weighted images.1 CMBs were defined as focal round lesions less than 10 mm in size with low signal on T2-gradient echo images.1 All radiological parameters were rated by two neurologists (K.W.N. and H.Y.J.), and disagreements were resolved by discussion with a third rater (H.M.K.).

4. Statistical analysis

All statistical analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, NY, USA). Univariate linear regression analyses were conducted to identify possible predictors for WMH volumes. Continuous variables with skewed data were transformed into a squared root scale, including WMH volumes. Then, variables with p<0.10 were introduced into the multivariable linear regression analysis along with age and sex as confounders. Since SBI and CMBs are binary outcome variables, we used multivariable logistic regression analyses for both. In addition, we investigated the relationship between ESR and demographic, clinical, and laboratory parameters in order to understand the characteristics of subjects with high ESR. For this analysis, we used a simple linear regression analysis. All variables with a p<0.05 were considered statistically significant in this study.


A total of 2,553 participants were evaluated (mean age: 57±10 years, male sex: 54%). The mean WMH volumes were 2.53±6.06 mL. SBI and CMB were found in 193 (7.6%) and 108 (4.2%), respectively. The mean ESR was 12±13 mm/hour. Other detailed baseline characteristics are shown in Table 1.
In univariate linear regression analysis, WMH volumes were significantly associated with age, hypertension, diabetes, hyperlipidemia, current smoking, systolic and diastolic BP, hemoglobin A1c levels, fasting glucose levels, total cholesterol levels, WBC counts, ESR, and use of anti-platelet agents (Table 2).
In multivariable linear regression analysis, ESR (β=0.027, 95% confidence interval [CI]=0.001 to 0.053, p=0.043) showed significant association with WMH volumes after adjusting for confounders. Age (β=0.046, 95% CI=0.042 to 0.051, p<0.001), hypertension (β=0.187, 95% CI=0.092 to 0.281, p<0.001), and WBC counts (β=0.042, 95% CI=0.018 to 0.067, p=0.001) were also significantly associated with WMH volumes, being independent from ESR (Table 3). On the other hand, neither SBI nor CMBs showed statistical significance with ESR (Supplementary Table 1).
In our data, ESR were associated with older age, female sex, diabetes, hyperlipidemia, current smoking, diastolic BP, hemoglobin A1c level, fasting glucose level, total cholesterol level, and hs-CRP level (Table 4).


In this study, we found that high ESR were associated with larger WMH volumes in a healthy population. In addition, WMH volume was closely related to WBC counts, and ESR was not statistically significant with SBI and CMBs. Given these findings, WMH appears to be more closely related to inflammatory pathology than other cSVD subtypes.
The exact mechanisms explaining the close relationship between ESR and WMH volume are unclear. However, we suggested several plausible hypotheses. First, it may be due to the destruction of the blood-brain barrier (BBB) by endothelial dysfunction. Inflammatory cytokines and reactive oxygen species arising from subclinical inflammation conditions can interfere with the secretion of nitric oxide by endothelial cells.19,21 Alternatively, the BBB itself may be mechanically damaged by an upregulated inflammatory cascade.19,22 Damaged BBB, functionally or mechanically, causes periventricular infiltration of several toxic materials (e.g., protease, immunoglobulin, and complement components), and can cause WMH by damaging the surrounding neural tissues.8,19,23 In addition, damaged BBB can prevent clearance of interstitial fluid through the glymphatic pathway, which can also lead to WMH.1,19 In our data, not only ESR but also elevated WBC counts showed a positive correlation with WMH volume, so this hypothesis seems valid. Second, chronic diffuse hypoperfusion may have been involved. The aforementioned decrease in nitric oxide production of endothelium can also decrease the ability to control cerebral perfusion through autoregulation.23,24 In addition, subclinical inflammation may prevent the proliferation of vascular smooth muscle cells and proceeds to fibrosis, causing atherosclerosis of small arterioles permanently.23,25,26 This is evidenced by several results showing that ESR is closely related to arterial stiffness in previous studies.15 In addition to small vessels, ESR has been shown to be closely correlated with atherosclerosis of large vessels.11,12 Chronic diffuse hypoperfusion caused by the stenosis of such large and small vessels is sufficient to grow WMH volumes. Last, it may simply be the result of ESR and WMH sharing multiple risk factors. Of course, subclinical inflammation is known to be closely related to several metabolic diseases.27 However, in our data, ESR showed a close correlation with older age, diabetes, hyperlipidemia, high BP, hs-CRP level, but not with WBC counts. Therefore, although it has not yet been identified, there may be a link between them through pathway other than the inflammation.
Interestingly, ESR showed a close association only with WMH and no statistical significance with SBI or CMBs. This phenomenon is interpreted as the fact that other pathological mechanisms unrelated to subclinical inflammation and endothelial dysfunction play many roles in the development of SBI and CMBs. In addition to lipohyalinosis, it is known that embolism caused by proximal sources and microatheroma are involved in SBI development.3,7 In case of CMBs, lobar and deep CMBs are caused by different mechanisms, and hypertensive insult or amyloid angiopathy can affect this.1,6 However, in addition to differences in mechanisms, these statistical results may have arisen due to the unusually low prevalence of SBI and CMBs in our young and healthy study population.
There are several caveats to interpret our results. First, this study is a retrospective cross-sectional design. Therefore, we can only prove the association between the ESR and the WMH volume, not the causal relationship. For this, further prospective study is needed. Second, we conducted a study on a relatively young and healthy population. Thus, the influence of age and various vascular risk factors may have been relatively underestimated, and the influence of ESR may have been overestimated. Third, in order to accurately measure the WMH volume, the whole brain volume should have been measured as well. By standardizing on the basis of the ratio between the two, it was possible to minimize the difference due to the head size. Fourth, ESR is a parameter that is affected by various medical conditions such as sex, obesity, menstruation, and medication. Therefore, when applied in practice, it must be judged comprehensively with the clinical situation or other biomarkers. Last, we measured the periventricular WMH and subcortical WMH together when rating the WMH volumes. In previous studies, different mechanisms and characteristics have been reported between the two areas of WMH.28 Due to technical limitations, this study could not separate the two. Interesting results can be obtained if we can examine the relationship between ESR and WMH in the periventricular and subcortical areas respectively.
In conclusion, we demonstrated that ESR was closely related to WMH volume in a healthy population. If we classify high-risk groups through ESR and manage each of them appropriately, it may be helpful in preventing the development of WMH. By doing so, we will be able to prevent the occurrence of several neurological disorders in the subclinical stage before symptoms develop. However, our findings are needed to be validated in further prospective studies.

Supplementary Material

Supplementary Table 1.

Multivariable logistic regression analysis of possible predictors for silent brain infarct and cerebral microbleeds


Conflicts of Interest
No potential conflicts of interest relevant to this article was reported.

Table 1.
Baseline characteristics (total n=2,553)
Age (years) 57±10
Sex (male) 1,396 (54.7)
Body mass index (kg/m2) 24.17±3.06
Hypertension 656 (25.7)
Diabetes 404 (15.8)
Hyperlipidemia 708 (27.7)
Ischemic heart disease 107 (4.2)
Current smoking 449 (17.6)
Systolic blood pressure (mmHg) 125±15
Diastolic blood pressure (mmHg) 75±11
HbA1c (%) 5.9±0.8
Fasting glucose (mg/dL) 97±23
Total cholesterol (mg/dL) 199±36
White blood cell (×103/μL) 5.46±1.63
Erythrocyte sedimentation rate (mm/hours) 12±13
High-sensitivity C-reactive protein (mg/dL) 0.17±0.67
Anti-platelet agent use 320 (12.5)
White matter hyperintensity (mL) 2.53±6.06
Silent brain infarct 193 (7.6)
Cerebral microbleeds 108 (4.2)

Values are presented as number (%) or mean±standard deviation.

Table 2.
Univariate linear regression analysis between white matter hyperintensity volume and demographic, clinical, laboratory, and radiological factors
β changes in square root of WMH volume (95% CI) p-value
Age (years) 0.049 (0.045 to 0.053) <0.001
Sex (male) 0.011 (-0.074 to 0.095) 0.804
Body mass index (kg/m2) 0.001 (-0.014 to 0.014) 0.998
Hypertension 0.445 (0.351 to 0.540) <0.001
Diabetes 0.391 (0.277 to 0.505) <0.001
Hyperlipidemia 0.097 (0.003 to 0.191) 0.042
Ischemic heart disease 0.122 (-0.087 to 0.332) 0.252
Current smoking -0.187 (-0.297 to -0.077) 0.001
Systolic blood pressure (mmHg) 0.009 (0.007 to 0.012) <0.001
Diastolic blood pressure (mmHg) 0.006 (0.002 to 0.010) 0.002
HbA1c (%)* 0.851 (0.575 to 1.128) <0.001
Fasting glucose, mg/dL* 0.126 (0.086 to 0.166) <0.001
Total cholesterol (mg/dL) -0.002 (-0.003 to 0.000) 0.008
White blood cell (x103/μL) 0.051 (0.025 to 0.076) <0.001
Erythrocyte sedimentation rate (mm/hours)* 0.078 (0.052 to 0.104) <0.001
High-sensitivity CRP (mg/dL)* 0.021 (-0.121 to 0.163) 0.771
Anti-platelet agent use 0.323 (0.197 to 0.449) <0.001

WMH; white matter hyperintensity, CRP; C-reactive protein.

* These variables were introduced as squared root scale.

Table 3.
Multivariate linear regression analysis of possible predictors for white matter hyperintensity volume
β changes in square root of WMH volume (95% CI) p-value
Age (years) 0.046 (0.042 to 0.051) <0.001
Sex (male) 0.055 (-0.033 to 0.143) 0.219
Body mass index (kg/m2) -0.008 (-0.021 to 0.004) 0.203
Hypertension 0.187 (0.092 to 0.281) <0.001
Diabetes 0.093 (-0.015 to 0.201) 0.091
Hyperlipidemia -0.053 (-0.139 to 0.033) 0.226
Current smoking 0.008 (-0.102 to 0.118) 0.893
White blood cell (x103/μL) 0.042 (0.018 to 0.067) 0.001
Erythrocyte sedimentation rate (mm/hours)* 0.027 (0.001 to 0.053) 0.043
Anti-platelet agent -0.002 (-0.121 to 0.118) 0.978

WMH; white matter hyperintensity.

* These variables were introduced as squared root scale.

Table 4.
Univariate linear regression analysis between erythrocyte sedimentation rate and demographic, clinical, and laboratory parameters
β changes in square root of ESR (95% CI) p-value
Age (years) 0.036 (0.029 to 0.042) <0.001
Sex (male) -1.235 (-1.351 to -1.119) <0.001
Body mass index (kg/m2) -0.020 (-0.040 to 0.000) 0.055
Hypertension 0.072 (-0.071 to 0.215) 0.324
Diabetes 0.312 (0.141 to 0.483) <0.001
Hyperlipidemia 0.167 (0.027 to 0.306) 0.019
Ischemic heart disease -0.004 (-0.316 to 0.308) 0.978
Current smoking -0.539 (-0.702 to -0.376) <0.001
Systolic blood pressure (mmHg) -0.003 (-0.007 to 0.001) 0.173
Diastolic blood pressure (mmHg) -0.013 (-0.018 to -0.007) <0.001
HbA1c (%)* 1.214 (0.802 to 1.626) <0.001
Fasting glucose (mg/dL)* 0.103 (0.044 to 0.162) 0.001
Total cholesterol (mg/dL) 0.003 (0.001 to 0.005) 0.001
White blood cell (x103/μL) -0.003 (-0.041 to 0.035) 0.872
High-sensitivity CRP (mg/dL)* 1.621 (1.419 to 1.822) <0.001
Anti-platelet agent use -0.022 (-0.211 to 0.167) 0.820

ESR; erythrocyte sedimentation rate, CRP; C-reactive protein.

* These variables were introduced as squared root scale.


1. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822-838.
crossref pmid pmc
2. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic whole-brain disease. Stroke Vasc Neurol. 2016;1:83-92.
crossref pmid pmc
3. Lee EJ, Kang DW, Warach S. Silent new brain lesions: innocent bystander or guilty party? J Stroke. 2016;18:38-49.
crossref pmid
4. Appleton JP, Woodhouse LJ, Adami A, Becker JL, Berge E, Cala LA, et al. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke. Neurology. 2020;94:e439-e452.
crossref pmid pmc
5. Rost NS, Rahman RM, Biffi A, Smith EE, Kanakis A, Fitzpatrick K, et al. White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology. 2010;75:1670-1677.
crossref pmid pmc
6. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013;12:483-497.
crossref pmid
7. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689-701.
crossref pmid
8. Wardlaw JM. Blood-brain barrier and cerebral small vessel disease. J Neurol Sci. 2010;299:66-71.
crossref pmid
9. Yoshida M, Higashi K, Kobayashi E, Saeki N, Wakui K, Kusaka T, et al. Correlation between images of silent brain infarction, carotid atherosclerosis and white matter hyperintensity, and plasma levels of acrolein, IL-6 and CRP. Atherosclerosis. 2010;211:475-479.
crossref pmid
10. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology. 2012;78:720-727.
crossref pmid
11. Erikssen G, Liestøl K, Bjørnholt JV, Stormorken H, Thaulow E, Erikssen J. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur Heart J. 2000;21:1614-1620.
crossref pmid
12. Natali A, L’Abbate A, Ferrannini E. Erythrocyte sedimentation rate, coronary atherosclerosis, and cardiac mortality. Eur Heart J. 2003;24:639-648.
crossref pmid
13. Li C, Zhang Q, Wang Q, Zhong J, Wang L, Li K, et al. Prognostic values of the SYNTAX score II and the erythrocyte sedimentation rate on long-term clinical outcomes in STEMI patients with multivessel disease: a retrospective cohort study. BMC Cardiovasc Disord. 2020;20:213.
crossref pmid pmc
14. Chamorro A, Vila N, Ascaso C, Saiz A, Montalvo J, Alonso P, et al. Early prediction of stroke severity. Role of the erythrocyte sedimentation rate. Stroke. 1995;26:573-576.
15. De Silva DA, Woon FP, Gan HY, Chen C, Chang HM, Cameron J, et al. Arterial stiffness is associated with raised levels of the inflammatory marker erythrocyte sedimentation rate among ischaemic stroke patients. Intern Med J. 2008;38:918-920.
crossref pmid
16. Zhou J, Wu J, Zhang J, Xu T, Zhang H, Zhang Y, et al. Association of stroke clinical outcomes with coexistence of hyperglycemia and biomarkers of inflammation. J Stroke Cerebrovasc Dis. 2015;24:1250-1255.
crossref pmid
17. Xie D, Hu D, Zhang Q, Sun Y, Li J, Zhang Y. Increased high-sensitivity C-reactive protein, erythrocyte sedimentation rate and lactic acid in stroke patients with internal carotid artery occlusion. Arch Med Sci. 2016;12:546-551.
crossref pmid
18. Balestrino M, Partinico D, Finocchi C, Gandolfo C. White blood cell count and erythrocyte sedimentation rate correlate with outcome in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 1998;7:139-144.
crossref pmid
19. Nam KW, Kwon HM, Jeong HY, Park JH, Kim SH, Jeong SM, et al. High neutrophil to lymphocyte ratio is associated with white matter hyperintensity in a healthy population. J Neurol Sci. 2017;380:128-131.
crossref pmid
20. Nam KW, Kwon HM, Jeong HY, Park JH, Kim SH, Jeong SM, et al. Cerebral white matter hyperintensity is associated with intracranial atherosclerosis in a healthy population. Atherosclerosis. 2017;265:179-183.
crossref pmid
21. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol. 2000;20:131-147.

22. Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2017;60:1-12.
crossref pmid
23. Hassan A, Hunt BJ, O’Sullivan M, Parmar K, Bamford JM, Briley D, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain. 2003;126:424-432.
crossref pmid
24. Bakker SL, de Leeuw FE, de Groot JC, Hofman A, Koudstaal PJ, Breteler MM. Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly. Neurology. 1999;52:578-583.
25. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004;11 Suppl 1:S56-S64.
crossref pmid
26. Cloonan L, Fitzpatrick KM, Kanakis AS, Furie KL, Rosand J, Rost NS. Metabolic determinants of white matter hyperintensity burden in patients with ischemic stroke. Atherosclerosis. 2015;240:149-153.
crossref pmid pmc
27. Mardi T, Toker S, Melamed S, Shirom A, Zeltser D, Shapira I, et al. Increased erythropoiesis and subclinical inflammation as part of the metabolic syndrome. Diabetes Res Clin Pract. 2005;69:249-255.
28. Lee KO, Woo MH, Chung D, Choi JW, Kim NK, Kim OJ, et al. Differential impact of plasma homocysteine levels on the periventricular and subcortical white matter hyperintensities on the brain. Front Neurol. 2019;10:1174.
crossref pmid pmc
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 0 Crossref
  •   Scopus
  • 341 View
  • 9 Download
Related articles in AC


Browse all articles >

Editorial Office
1021 Tongil-ro, Eunpyeong-gu, Seoul, 03312, Republic of Korea
Tel: +82-2-2030-3749    E-mail: ksn@neurosonology.or.kr                

Copyright © 2021 by Korean Society of Neurosonology.

Developed in M2PI

Close layer
prev next